TopoDx

TopoDx, Inc.

10 Investors
Medical Diagnostics
ATLANTA, GA

TopoDx, Inc. is a biotechnology startup developing a diagnostic tool to combat the global challenge of antibiotic resistance. Spun out of research from Georgia Tech and Emory University, the company's technology aims to rapidly determine antibiotic susceptibility, reducing test times from days to hours. This allows clinicians to make faster, more informed treatment decisions and improve patient outcomes.

Products & Team

Rapid Antibiotic Susceptibility Diagnostic Test

Diagnostic DeviceSeed

TopoDx is developing a countertop diagnostic device, roughly the size of a large microwave, that houses its core microbial test. The system utilizes white-light interferometry to observe the physical response of bacterial colonies to antibiotics in real-time. By measuring changes in colony topography at the nanometer level, the technology can quickly determine if the bacteria are resistant or susceptible to a specific drug.

Value Proposition

The product directly addresses the critical bottleneck of slow diagnostic times in treating infections. By providing rapid results, it enables clinicians to quickly prescribe targeted, effective antibiotics, which can improve patient outcomes, reduce the reliance on broad-spectrum drugs, and help combat the rise of antibiotic-resistant bacteria.

Pain Points

Customers face significant delays with current testing methods, which can take up to five days. This uncertainty leads to the initial use of broad-spectrum antibiotics, potentially contributing to antibiotic resistance and resulting in suboptimal treatment for the patient.

Provides antibiotic susceptibility results in under four hoursUtilizes white-light interferometry to assess bacterial responseMeasures nanometer-scale changes in bacterial colony topographyDesigned as a countertop device for use in clinical settings
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
ATLANTA, GA
Primary headquarters

Funding History

Total Raised:
$1.5M
E

Equity Offering

July 2025
$2.0M
Target
Use of Proceeds
Salary for CEO & President.
Progress
75%
Raised
$1.5M
Target
$2.0M
#000207559025000002